Type:10 Tablets
Generic Name:Naproxen
Manufacturer:Eskayef Pharmaceuticals Ltd.
Price:৳70.00
Rheumatoid arthritis, Ankylosing spondylitis, Post-operative pain, Dysmenorrhea, Acute gout, Acute migraine attacks, Renal colic, Mild to moderate pain, Tendonitis, Osteoarthritis (degenerative arthritis), Acute musculoskeletal disorders, Bursitis
Should be taken with food.
Adults Oral: Pain 500 mg PO initially, then 250 mg PO q6-8hr or 500 mg PO q12hr PRN; not to exceed 1250 mg/day naproxen base on day 1; subsequent daily doses should not exceed 1000 mg naproxen base Extended release: 750-1000 mg PO qDay; may temporarily increase to 1500 mg/day if tolerated well and clinically indicated Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis 500-1000 mg/day PO divided q12hr; may increase to 1500 mg/day if tolerated well for limited time Extended release: 750-1000 mg PO qDay; may temporarily increase to 1500 mg/day if tolerated well and clinically indicated Dysmenorrhea 500 mg PO initially, then 250 mg PO q6-8hr or 500 mg PO q12hr (long-acting formula); not to exceed 1250 mg/day on first day; subsequent doses should not exceed 1000 mg/day naproxen base Gout, Acute 750 mg PO initially, followed by 250 mg q8hr until attack subsides Extended release: 1000-1500 mg qDay, followed by 1000 mg qDay until attack subsides
Pain >12 years 500 mg PO initially, then 250 mg PO q6-8hr or 500 mg PO q12hr PRN; not to exceed 1250 mg/day naproxen base on day 1; subsequent daily doses should not exceed 1000 mg naproxen base Extended release: 750-1000 mg PO qDay; may temporarily increase to 1500 mg/day if tolerated well and clinically indicated Juvenile Idiopathic Arthritis >2 years: 10 mg/kg/day oral suspension PO divided q12hr; not to exceed 15 mg/kg/day
Renal impairment: CrCl <30 mL/min: Use not recommended Severe: Contraindicated.
Hypersensitivity. Aspirin or NSAID allergy. Perioperative pain in the setting of CABG surgery. Pregnancy (3rd trimester).
Naproxen, a propionic acid derivative, is a prototypical NSAID. It reversibly inhibits the cyclooxygenase-1 and -2 (COX-1 and -2) enzymes, thus resulting in reduced synthesis of prostaglandin precursors. It can inhibit platelet aggregation, has anti-inflammatory, analgesic and antipyretic actions.
Patient w/ known CV disease or risk factors for CV disease, history of GI bleeding or peptic ulceration, fluid retention or heart failure. Hepatic and renal impairment. Elderly. Pregnancy and lactation. Patient Counselling May impair ability to drive and operate machinery. Monitoring Parameters BP should be monitored closely during initiation and throughout therapy. Perform periodically renal function, CBC and chemistry profile in patients receiving long-term therapy. Lactation: Drug excreted in breast milk; effect on infant unknown; not recommended
1-10% Abdominal pain (3-9%),Constipation (3-9%),Dizziness (3-9%),Drowsiness (3-9%),Headache (3-9%),Heartburn (3-9%),Nausea (3-9%),Edema (3-9%),GI bleeding (1-4%),GI perforation (1-4%),Lightneadedness (<3%),GI ulcers (1-4%),Fluid retention (3-9%),Diarrhea (1-3%),Stomatitis (<3%),Diverticulitis (1-3%),Dyspnea (3-9%),Hearing disturbances (<3%) <1% Meaningful (3 × upper limit of normal) elevation of serum alanine aminotransferase or aspartate aminotransferase
Pregnancy category: C; D in 3rd trimester or near delivery.
May enhance methotrexate toxicity. Reduced BP response to ACE inhibitors or angiotensin II receptor antagonists. Increased risk of serious GI events (e.g. ulcer) w/ aspirin. Increased risk of GI bleeding w/ warfarin. May reduce the natriuretic effects of furosemide or thiazide diuretics. May increase serum lithium concentrations and reduce renal lithium clearance. Delayed absorption w/ antacids, colestyramine or sucralfate. May interfere w/ the antihypertensive effects of beta-blockers (e.g. propranolol). May increase serum levels w/ probenecid.
